Arlene Siefker-Radtke, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines some areas of unmet needs in the treatment and management of bladder cancer, including the outcomes of “immunologically cold” tumours, determining mechanisms of resistance as well as novel therapies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).